FDA proposes adding bemotrizinol to U.S. sunscreens — first new active ingredient in more than 25 years
The FDA has issued a proposed order to add bemotrizinol to the list of approved sunscreen active ingredients — the first expansion in over 26 years — promising enhanced broad-spectrum UVA and UVB protection with low skin absorption.
Key takeaways
- Proposed order: The agency issued a proposed order to add bemotrizinol as an over‑the‑counter sunscreen active ingredient — see the FDA press announcement.
- Safety & protection: FDA review found broad‑spectrum UVA and UVB protection, low skin absorption and rare irritation — see FDA supporting documents.
- Concentration & forms: Proposal mirrors DSM’s request for up to 6% bemotrizinol across common forms (lotions, sprays, sticks and creams) — details in the FDA proposed order and materials.
- Market timing & exclusivity: DSM plans to market bemotrizinol as Parsol Shield (expected 2026) with an 18‑month exclusivity period — reported in industry reporting.
What bemotrizinol is and why it matters
Bemotrizinol is an ultraviolet filter already used outside the U.S., engineered to absorb a wide band of UV light. It helps protect against shorter‑wave UVB rays (sunburn) and longer‑wave UVA rays (deeper skin damage and some cancers).
The FDA’s review found that bemotrizinol offers strong UVA/UVB protection while showing low absorption into the body and minimal irritation in reviewed studies — see the FDA press announcement and supporting documents.
Regulatory details and limits
Concentration: DSM Nutritional Products requested permission for bemotrizinol at concentrations up to 6%; the FDA’s proposed order adopts that limit and covers common product forms such as oils, lotions, creams, gels, butters, pastes, ointments, sticks and sprays — see the FDA documents and legal overview at legal analysis.
The FDA’s proposed order labels bemotrizinol as generally recognized as safe and effective (GRASE) for people 6 months and older, which would allow nonprescription use if the proposal is finalized following public comment and rulemaking — see FDA supporting materials.
Exclusivity and what it means for consumers
DSM plans to introduce bemotrizinol in the U.S. under the brand name Parsol Shield, expected later in 2026. The company reportedly has an 18‑month exclusivity window before other manufacturers can use the ingredient, which may temporarily limit availability and affect pricing — reported in industry reporting.
Note: early availability may be concentrated in a single brand during the exclusivity period; wider availability and price competition typically follow after exclusivity ends.
Why some nuance matters: proposed order vs. final rule
Media accounts sometimes describe the FDA action as an immediate “approval.” In fact, the agency issued a proposed order, which initiates a formal process including a public comment period and further administrative steps before a binding final rule is issued. The proposed action is an important step in modernizing the OTC sunscreen monograph system — see FDA proposed order and supporting materials and FDA Q&A on OTC sunscreen orders.
Statements from agency leaders
“We’re continuing to modernize the regulation of sunscreen and other over‑the‑counter drug products… Americans deserve timely access to the best safe, effective and consumer‑friendly over‑the‑counter products available.” — FDA Commissioner Marty Makary, MD, MPH
Karen Murry, MD, acting director of the Office of Nonprescription Drugs, called bemotrizinol “a welcome addition to the current array of effective sunscreen active ingredients already available to American consumers,” and said the agency looks forward to working with companies to bring other new active ingredients to market more quickly — see the FDA press release and supporting materials.
Public health advice still unchanged
Despite potential new ingredients, the FDA continues to recommend a layered approach to sun safety: use broad‑spectrum sunscreen with SPF 15 or higher, wear protective clothing, seek shade and limit time in direct sun to reduce skin cancer and premature aging risks — see the FDA guidance.
Implications for Grand Terrace, California
Economic impact
Grand Terrace retailers, pharmacies and outdoor‑supply stores could see demand for higher‑performance sunscreens. Early sales may favor vendors carrying Parsol Shield, followed by broader product availability after the exclusivity period.
Political consequences
Although primarily regulatory, the FDA action touches local public health priorities. City and county leaders promoting skin‑cancer prevention may find new messaging opportunities; they should monitor the public‑comment and final‑rule timeline before changing procurement or official guidance.
Social effects
Families, youth sports programs and outdoor workers could benefit from sunscreens combining strong UVA/UVB protection with lower irritation risk. The FDA’s proposed allowance for children 6 months and older could be important for parents choosing infant‑safe products.
Cultural relevance
In a region where outdoor life is central, access to advanced sunscreen ingredients aligns with resident priorities for practical health tools. Bemotrizinol’s international use may reassure consumers familiar with similar products overseas.
Practical applications for residents
- Early adopters: Watch for the Parsol Shield launch, likely in 2026; initial availability may be limited to one brand — see industry reporting.
- Shopping & price: Expect exclusivity to affect price and availability; broader, cheaper options may follow after 18 months.
- Use & age guidance: If finalized, bemotrizinol would be allowed for adults and children 6 months and older — see the FDA announcement.
- Continuing precautions: Regardless of ingredient, follow FDA recommendations for broad‑spectrum SPF 15+ and other sun‑safety measures.
